ERNA
Ernexa Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $7.82M |
| P/E Ratio (TTM) | 0.01 |
| Forward P/E | -0.70 |
| EPS (TTM) | $1214.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -2505.61% |
| Debt/Equity | 5.67 |
| Recommendation | None |
| Analyst Target | $30.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 54.2 |
| Beta | 2.47 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $71.50 |
| 52-Week Low | $3.18 |
| 50-Day Avg | $7.62 |
| 200-Day Avg | $19.79 |
| Avg Volume | $1.68M |
| Volume | 96.9K |
Performance Analysis
BULLISHERNA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report